Literature DB >> 6297384

Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.

I A Bakker-Woudenberg, J C van den Berg, M F Michel.   

Abstract

The efficacies of several dosage schedules of cefazolin, cefotaxime, and ceftazidime, started 12 or 36 h after infection, were examined in experimental pneumonia caused by Klebsiella pneumoniae in rats. The therapeutic activities of the cephalosporins were compared with the antibacterial activities in vitro and the serum concentration curves. The course of experimental pneumonia was rapid and characterized by tissue necrosis. Response to antimicrobial treatment was evaluated with respect to mortality and numbers of bacteria in lung (left lobe), blood, and pleural fluid. When antibiotic treatment was started early, i.e., 12 h after bacterial inoculation, cefotaxime and ceftazidime were equally effective and superior to cefazolin. Eleven doses of 10 mg of cefotaxime or ceftazidime per kg or 11 doses of 60 mg of cefazolin per kg were required to improve the survival rate. With a delay in administration to 36 h after inoculation, the efficacy of the cephalosporins decreased markedly. In the three dosages tested, cefazolin was ineffective. Survival improved with the administration of nine doses of 60 mg of cefotaxime per kg or nine doses of 10 mg of ceftazidime per kg. These results are not in accordance with the ratio of in vitro activities of cefotaxime and ceftazidime or the serum concentration curves.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6297384      PMCID: PMC185718          DOI: 10.1128/AAC.22.6.1042

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Infections in cancer patients.

Authors:  G P Bodey
Journal:  Cancer Treat Rev       Date:  1975-06       Impact factor: 12.111

2.  Gram-negative bacillary pneumonia in the compromised host.

Authors:  M Valdivieso; B Gil-extremera; J Zornoza; V Rodriquez; G P Bodey
Journal:  Medicine (Baltimore)       Date:  1977-05       Impact factor: 1.889

3.  Indolent pulmonary abscess associated with Klebsiella and Enterobacter.

Authors:  W P Reed
Journal:  Am Rev Respir Dis       Date:  1973-06

4.  Klebsiella bacteremia in cancer patients.

Authors:  T Umsawasdi; E A Middleman; M Luna; G P Bodey
Journal:  Am J Med Sci       Date:  1973-06       Impact factor: 2.378

5.  Recent experience with bacteremia in patients presenting cancer.

Authors:  J Klastersky; D Weerts
Journal:  Eur J Cancer       Date:  1973-01       Impact factor: 9.162

6.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

7.  Changing patterns of infection in cancer patients.

Authors:  H Gaya; M H Tattersall; R M Hutchinson; A S Spiers
Journal:  Eur J Cancer       Date:  1973-06       Impact factor: 9.162

Review 8.  Fever and infection in leukemic patients: a study of 494 consecutive patients.

Authors:  G P Bodey; V Rodriguez; H Y Chang
Journal:  Cancer       Date:  1978-04       Impact factor: 6.860

9.  Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

Authors:  R Wise; P J Wills; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

10.  Efficacy of antimicrobial therapy in experimental rat pneumonia: effects of impaired phagocytosis.

Authors:  I A Bakker-Woudenberg; J Y de Jong-Hoenderop; M F Michel
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

View more
  16 in total

1.  Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Wil H F Goessens; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Drug treatment of pneumonia in the hospital. What are the choices?

Authors:  M Aoun; J Klastersky
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin.

Authors:  R M Schiffelers; G Storm; M T ten Kate; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; M T ten Kate; L Guo; P Working; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.

Authors:  Elisabeth J Ruijgrok; Marcel H A M Fens; Irma A J M Bakker-Woudenberg; Els W M van Etten; Arnold G Vulto
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue.

Authors:  R M Schiffelers; G Storm; I A Bakker-Woudenberg
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

7.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

8.  Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

9.  Immunization against fatal experimental Klebsiella pneumoniae pneumonia.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

10.  Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice.

Authors:  Y Iizawa; K Okonogi; R Hayashi; T Iwahi; T Yamazaki; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.